371 related articles for article (PubMed ID: 28325607)
1. Japanese Clinical Practice Guideline for Head and Neck Cancer.
Nibu KI; Hayashi R; Asakage T; Ojiri H; Kimata Y; Kodaira T; Nagao T; Nakashima T; Fujii T; Fujii H; Homma A; Matsuura K; Monden N; Beppu T; Hanai N; Kirita T; Kamei Y; Otsuki N; Kiyota N; Zenda S; Omura K; Omori K; Akimoto T; Kawabata K; Kishimoto S; Kitano H; Tohnai I; Nakatsuka T
Auris Nasus Larynx; 2017 Aug; 44(4):375-380. PubMed ID: 28325607
[TBL] [Abstract][Full Text] [Related]
2. The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients.
Hirasawa K; Okamoto I; Motohashi R; Sato H; Takase S; Agata A; Takeda A; Tsukahara K
Auris Nasus Larynx; 2017 Dec; 44(6):724-728. PubMed ID: 28237712
[TBL] [Abstract][Full Text] [Related]
3. Thermochemoradiation therapy using superselective intra-arterial infusion via superficial temporal and occipital arteries for oral cancer with N3 cervical lymph node metastases.
Mitsudo K; Koizumi T; Iida M; Iwai T; Oguri S; Yamamoto N; Itoh Y; Kioi M; Hirota M; Tohnai I
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e639-45. PubMed ID: 22543212
[TBL] [Abstract][Full Text] [Related]
4. [Planned neck dissection in the treatment of locally advanced head and neck squamous cell carcinoma].
Jiang L; Lou JL; Wang KJ; Fang MY; Fu ZF
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Feb; 53(2):92-96. PubMed ID: 29429177
[No Abstract] [Full Text] [Related]
5. Chemotherapy in locally advanced head and neck squamous cell carcinoma.
Gyawali B; Shimokata T; Honda K; Ando Y
Cancer Treat Rev; 2016 Mar; 44():10-6. PubMed ID: 26924194
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
[TBL] [Abstract][Full Text] [Related]
7. Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab.
Granados-García M; Aguilar-Ponce JL; Maldonado-Magos F; De la Garza-Salazar JG
ORL J Otorhinolaryngol Relat Spec; 2016; 78(6):320-333. PubMed ID: 28125819
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
[TBL] [Abstract][Full Text] [Related]
9. Sentinel node biopsy for oral cancer: A prospective multicenter Phase II trial.
Miura K; Hirakawa H; Uemura H; Yoshimoto S; Shiotani A; Sugasawa M; Homma A; Yokoyama J; Tsukahara K; Yoshizaki T; Yatabe Y; Matsuo K; Ohkura Y; Kosuda S; Hasegawa Y
Auris Nasus Larynx; 2017 Jun; 44(3):319-326. PubMed ID: 27496008
[TBL] [Abstract][Full Text] [Related]
10. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and individual patient data analysis of pediatric head and neck squamous cell carcinoma: An analysis of 217 cases.
Bhanu Prasad V; Mallick S; Upadhyay AD; Rath GK
Int J Pediatr Otorhinolaryngol; 2017 Jan; 92():75-81. PubMed ID: 28012539
[TBL] [Abstract][Full Text] [Related]
12. Economic analyses in squamous cell carcinoma of the head and neck: a review of the literature from a clinical perspective.
de Souza JA; Santana IA; de Castro G; de Lima Lopes G; Tina Shih YC
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):989-996. PubMed ID: 25035201
[TBL] [Abstract][Full Text] [Related]
13. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
[TBL] [Abstract][Full Text] [Related]
15. Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options.
Strojan P; Ferlito A; Langendijk JA; Corry J; Woolgar JA; Rinaldo A; Silver CE; Paleri V; Fagan JJ; Pellitteri PK; Haigentz M; Suárez C; Robbins KT; Rodrigo JP; Olsen KD; Hinni ML; Werner JA; Mondin V; Kowalski LP; Devaney KO; de Bree R; Takes RP; Wolf GT; Shaha AR; Genden EM; Barnes L
Head Neck; 2013 Feb; 35(2):286-93. PubMed ID: 22034062
[TBL] [Abstract][Full Text] [Related]
16. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.
Brizel DM; Prosnitz RG; Hunter S; Fisher SR; Clough RL; Downey MA; Scher RL
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1418-23. PubMed ID: 15050318
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
19. Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab.
Montal R; Oliva M; Taberna M; De Avila L; Rovira A; Cos M; Mañós M; Navarro V; Nogués J; Lozano A; Rodríguez L; Vilajosana E; Vázquez S; Mesia R
Clin Transl Oncol; 2016 Nov; 18(11):1140-1146. PubMed ID: 26960559
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
Tinhofer I; Hristozova T; Stromberger C; Keilhoiz U; Budach V
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e685-90. PubMed ID: 22583603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
